Pirfenidone (BioDeep_00000182466)
human metabolite blood metabolite
代谢物信息卡片
5-methyl-1-phenyl-1,2-dihydropyridin-2-one
化学式: C12H11NO (185.0840596)
中文名称: 吡非尼酮
谱图信息:
最多检出来源 Homo sapiens(blood) 0.63%
分子结构信息
SMILES: CC1=CN(C(=O)C=C1)C1=CC=CC=C1
InChI: InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
C26170 - Protective Agent > C797 - Radioprotective Agent
D000893 - Anti-Inflammatory Agents
D000970 - Antineoplastic Agents
D018501 - Antirheumatic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:32016
- PubChem: 40632
- HMDB: HMDB0256594
- DrugBank: DB04951
- ChEMBL: CHEMBL1256391
- Wikipedia: Pirfenidone
- chemspider: 37115
- CAS: 53179-13-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yulei Liang, Yanan Yan, Na Liu, Jiepeng Wang, Chaoyi Fang. Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis.
Journal of ethnopharmacology.
2024 Jul; 329(?):118153. doi:
10.1016/j.jep.2024.118153. [PMID: 38604513] - Xiuhua Wang, Wei Wan, Jing Lu, Peiqing Liu. Inhalable FN-binding liposomes or liposome-exosome hybrid bionic vesicles encapsulated microparticles for enhanced pulmonary fibrosis therapy.
International journal of pharmaceutics.
2024 May; 656(?):124096. doi:
10.1016/j.ijpharm.2024.124096. [PMID: 38583821] - Nana Liu, Yanqiu Song, Ting Liu, Hongyu Wang, Naihao Yu, Hui Ma. Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice.
The clinical respiratory journal.
2024 Jan; 18(1):e13731. doi:
10.1111/crj.13731. [PMID: 38286745] - Shan Yang, Renzi Zhang, Wenzhen Deng, Shichuan Chang, Yang Li, Sheng Li. Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.].
2023 Sep; ?(?):. doi:
10.1007/s00011-023-01776-2. [PMID: 37659014] - Ting Zhao, Bokai Gong, Shiqin Luo, Rongping Zhang, Ling Zhang, Yuan Huang, Huile Gao, Tao Gong. A fibroblastic foci-targeting and hypoxia-cleavable delivery system of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Acta biomaterialia.
2023 Jun; ?(?):. doi:
10.1016/j.actbio.2023.06.024. [PMID: 37356783] - Rong Xie, Shaodong Chen, Fang Li, Liu Yang, Bangliang Yu. Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.
Journal of biochemical and molecular toxicology.
2023 Feb; 37(2):e23251. doi:
10.1002/jbt.23251. [PMID: 36321572] - Mona M AbouSamra, Rania Elgohary, Soheir S Mansy. Innovated pirfenidone loaded lecithin nanocapsules for targeting liver fibrosis: Formulation, characterization and in vivo study.
International journal of pharmaceutics.
2023 Jan; 631(?):122539. doi:
10.1016/j.ijpharm.2022.122539. [PMID: 36572266] - Gang Wang, Xiaowan Zhou, Zengli Guo, Nan Huang, Juan Li, Yanfang Lv, Lulu Han, Wei Zheng, Dandan Xu, Dafei Chai, Huizhong Li, Liantao Li, Junnian Zheng. The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.
Cancer biology & therapy.
2022 12; 23(1):150-162. doi:
10.1080/15384047.2022.2035629. [PMID: 35130111] - Junying Kong, Ying Deng. Pirfenidone alleviates vascular intima injury caused by hyperhomocysteinemia.
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
2022 10; 41(10):813-819. doi:
10.1016/j.repc.2021.12.011. [PMID: 36210587] - Xian Wu, Hao Gou, Ou Zhou, Huijun Qiu, Hanmin Liu, Zhou Fu, Lina Chen. Human umbilical cord mesenchymal stem cells combined with pirfenidone upregulates the expression of RGS2 in the pulmonary fibrosis in mice.
Respiratory research.
2022 Oct; 23(1):270. doi:
10.1186/s12931-022-02192-6. [PMID: 36182915] - Renzi Zhang, Yiwen Tan, Chaoying Yong, Yang Jiao, Xumao Tang, Daoxin Wang. Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway.
International immunopharmacology.
2022 Aug; 109(?):108805. doi:
10.1016/j.intimp.2022.108805. [PMID: 35504205] - Shuyu Li, Qixin Yang, Feilong Chen, Linhua Tian, Jinhai Huo, Yanli Meng, Qingfa Tang, Weiming Wang. The antifibrotic effect of pheretima protein is mediated by the TGF-β1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis.
Journal of ethnopharmacology.
2022 Mar; 286(?):114901. doi:
10.1016/j.jep.2021.114901. [PMID: 34890730] - Junwei He, Xinxian Meng, Chen Meng, Jiayu Zhao, Yunsheng Chen, Zheng Zhang, Yixin Zhang. Layer-by-Layer Pirfenidone/Cerium Oxide Nanocapsule Dressing Promotes Wound Repair and Prevents Scar Formation.
Molecules (Basel, Switzerland).
2022 Mar; 27(6):. doi:
10.3390/molecules27061830. [PMID: 35335197] - Zongtao Zhou, Qiang Ren, Shixuan Jiao, Zongyu Cai, Xinqian Geng, Liming Deng, Bin Wang, Lijun Hu, Luyong Zhang, Ying Yang, Zheng Li. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
European journal of medicinal chemistry.
2022 Feb; 229(?):114061. doi:
10.1016/j.ejmech.2021.114061. [PMID: 34954593] - Liangliang Bi, Yanjie Huang, Jing Li, Xiaoqing Yang, Gailing Hou, Panpan Zhai, Qiushuang Zhang, Abubakari Adam Alhaji, Yueli Yang, Bo Liu. Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21.
Nephron.
2022; 146(1):110-120. doi:
10.1159/000519495. [PMID: 34724669] - Reem M Hazem, Samar A Antar, Yossef K Nafea, Ahmed A Al-Karmalawy, Mohamed A Saleh, Mona F El-Azab. Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor.
Life sciences.
2022 Jan; 288(?):120185. doi:
10.1016/j.lfs.2021.120185. [PMID: 34861286] - Giacomo Sgalla, Alessia Comes, Marialessia Lerede, Luca Richeldi. COVID-related fibrosis: insights into potential drug targets.
Expert opinion on investigational drugs.
2021 Dec; 30(12):1183-1195. doi:
10.1080/13543784.2021.2010188. [PMID: 34842488] - Murat Acat, Pinar Yildiz Gulhan, Serkan Oner, Muhammed Kamil Turan. Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography.
International journal of clinical practice.
2021 Dec; 75(12):e14961. doi:
10.1111/ijcp.14961. [PMID: 34624155] - Jun Matsumoto, Keisuke Sunohara, Yoshiko Mori, Hiroshi Nagaya, Shinichiro Inaba. Effects of pirfenidone on renal function in patients with interstitial pneumonia.
Renal failure.
2021 Dec; 43(1):879-881. doi:
10.1080/0886022x.2021.1925297. [PMID: 34018462] - Samar A Antar, Mohamed Kh ElMahdy, Ahmed E Khodir. A novel role of pirfenidone in attenuation acetic acid induced ulcerative colitis by modulation of TGF-β1 / JNK1 pathway.
International immunopharmacology.
2021 Dec; 101(Pt B):108289. doi:
10.1016/j.intimp.2021.108289. [PMID: 34710659] - Fengqin Zhang, Yanqiu Wei, Li He, Huilan Zhang, Qiongjie Hu, Huihui Yue, Jianhan He, Huaping Dai. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
Chinese medical journal.
2021 12; 135(3):368-370. doi:
10.1097/cm9.0000000000001614. [PMID: 34855641] - Xue Bai, Ping Nie, Yan Lou, Yuexin Zhu, Shan Jiang, Bing Li, Ping Luo. Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence.
European journal of pharmacology.
2021 Nov; 911(?):174503. doi:
10.1016/j.ejphar.2021.174503. [PMID: 34547247] - Chenchen Zang, Yan Zheng, Yanqing Wang, Lisha Li. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
European journal of medical research.
2021 Oct; 26(1):129. doi:
10.1186/s40001-021-00601-y. [PMID: 34717762] - Jorge Gutiérrez-Cuevas, Ana Sandoval-Rodríguez, Hugo Christian Monroy-Ramírez, Monica Vazquez-Del Mercado, Arturo Santos-García, Juan Armendáriz-Borunda. Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Cardiovascular drugs and therapy.
2021 10; 35(5):927-938. doi:
10.1007/s10557-020-07014-9. [PMID: 32621046] - Baokun Zhang, Zhenyu Ding, Jiqing Dong, Fangqi Lin, Zichao Xue, Jianguang Xu. Macrophage-mediated degradable gelatin-coated mesoporous silica nanoparticles carrying pirfenidone for the treatment of rat spinal cord injury.
Nanomedicine : nanotechnology, biology, and medicine.
2021 10; 37(?):102420. doi:
10.1016/j.nano.2021.102420. [PMID: 34182154] - Hai Zou, Sheng-Qing Li. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
Acta pharmacologica Sinica.
2021 08; 42(8):1376-1378. doi:
10.1038/s41401-020-00566-4. [PMID: 33188277] - Yiming Ma, Lijuan Luo, Xiangming Liu, Herui Li, Zihang Zeng, Xue He, Zijie Zhan, Yan Chen. Pirfenidone mediates cigarette smoke extract induced inflammation and oxidative stress in vitro and in vivo.
International immunopharmacology.
2021 Jul; 96(?):107593. doi:
10.1016/j.intimp.2021.107593. [PMID: 33819731] - Rebeca Escutia-Gutiérrez, J Samael Rodríguez-Sanabria, C Alejandra Monraz-Méndez, Jesús García-Bañuelos, Arturo Santos-García, Ana Sandoval-Rodríguez, Juan Armendáriz-Borunda. Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.
Scientific reports.
2021 06; 11(1):11709. doi:
10.1038/s41598-021-91187-2. [PMID: 34083664] - Seyed Hootan Hamidi, Sandhya Kadamboor Veethil, Seyedeh Harir Hamidi. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Pharmacological reports : PR.
2021 Jun; 73(3):712-727. doi:
10.1007/s43440-021-00255-x. [PMID: 33880743] - Elia Bari, Ilaria Ferrarotti, Laura Saracino, Sara Perteghella, Maria Luisa Torre, Luca Richeldi, Angelo Guido Corsico. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?.
Cells.
2021 05; 10(5):. doi:
10.3390/cells10051203. [PMID: 34068958] - Caiqing Wu, Ping Wai Or, Jones Iok Tong Chong, Isuru K K Pathirage Don, Ching Hymn Christopher Lee, Kaili Wu, Minbin Yu, David C C Lam, Yangfan Yang. Extended Delivery of Pirfenidone with Novel, Soft Contact Lenses In Vitro and In Vivo.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
2021 03; 37(2):75-83. doi:
10.1089/jop.2020.0058. [PMID: 33297836] - Chi Zhang, Zhao Wu, Jia-Wen Li, Kangan Tan, Wanna Yang, Hong Zhao, Gui-Qiang Wang. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
Journal of medical virology.
2021 03; 93(3):1378-1386. doi:
10.1002/jmv.26634. [PMID: 33107641] - Huachun Cui, Na Xie, Sami Banerjee, Jing Ge, Dingyuan Jiang, Tapan Dey, Qiana L Matthews, Rui-Ming Liu, Gang Liu. Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.
American journal of respiratory cell and molecular biology.
2021 01; 64(1):115-125. doi:
10.1165/rcmb.2020-0360oc. [PMID: 33074715] - Kimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Hiroki Sakaguchi, Shogo Miyazawa, Moritaka Suga, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Hiroki Takahashi. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Respiratory research.
2020 Nov; 21(1):316. doi:
10.1186/s12931-020-01582-y. [PMID: 33256760] - Soroush Seifirad. Pirfenidone: A novel hypothetical treatment for COVID-19.
Medical hypotheses.
2020 Nov; 144(?):110005. doi:
10.1016/j.mehy.2020.110005. [PMID: 32575019] - Maha H Sharawy, Marwa S Serrya. Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats.
Life sciences.
2020 Nov; 260(?):118454. doi:
10.1016/j.lfs.2020.118454. [PMID: 32950575] - Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, Raffaele La Porta, Antonio Vitiello. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?.
European journal of clinical pharmacology.
2020 Nov; 76(11):1615-1618. doi:
10.1007/s00228-020-02947-4. [PMID: 32594204] - Ayodeji Adegunsoye, Shehabaldin Alqalyoobi, Angela Linderholm, Willis S Bowman, Cathryn T Lee, Janelle Vu Pugashetti, Nandini Sarma, Shwu-Fan Ma, Angela Haczku, Anne Sperling, Mary E Strek, Imre Noth, Justin M Oldham. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Chest.
2020 10; 158(4):1526-1534. doi:
10.1016/j.chest.2020.04.066. [PMID: 32450241] - Wei-Ting Chang, Eugenio Ragazzi, Ping-Yen Liu, Sheng-Nan Wu. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.
European journal of pharmacology.
2020 Sep; 882(?):173237. doi:
10.1016/j.ejphar.2020.173237. [PMID: 32525005] - Jorge Luis Poo, Aldo Torre, Juan Ramón Aguilar-Ramírez, Mauricio Cruz, Luis Mejía-Cuán, Eira Cerda, Alfredo Velázquez, Angélica Patiño, Carlos Ramírez-Castillo, Laura Cisneros, Francisco Bosques-Padilla, Larissa Hernández, Frida Gasca, Francisco Flores-Murrieta, Samuel Treviño, Graciela Tapia, Juan Armendariz-Borunda, Linda E Muñoz-Espinosa. Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.
Hepatology international.
2020 Sep; 14(5):817-827. doi:
10.1007/s12072-020-10069-3. [PMID: 32813194] - Xufeng Peng, Hailin Guo, Jun Chen, Jihong Wang, Jianwen Huang. The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms.
The Prostate.
2020 09; 80(12):917-925. doi:
10.1002/pros.23995. [PMID: 32569423] - Mohammad AlQudah, Taben M Hale, Michael P Czubryt. Targeting the renin-angiotensin-aldosterone system in fibrosis.
Matrix biology : journal of the International Society for Matrix Biology.
2020 09; 91-92(?):92-108. doi:
10.1016/j.matbio.2020.04.005. [PMID: 32422329] - Shenzhi Zhou, Wei Li, Min Tian, Na Zhang, Xiaojing Yang, Weiwei Li, Ying Peng, Jiang Zheng. Metabolic Activation of Pirfenidone Mediated by Cytochrome P450s and Sulfotransferases.
Journal of medicinal chemistry.
2020 08; 63(15):8059-8068. doi:
10.1021/acs.jmedchem.9b02073. [PMID: 32643929] - Sebastiano Emanuele Torrisi, Nicolas Kahn, Carlo Vancheri, Michael Kreuter. Evolution and treatment of idiopathic pulmonary fibrosis.
Presse medicale (Paris, France : 1983).
2020 Jun; 49(2):104025. doi:
10.1016/j.lpm.2020.104025. [PMID: 32437841] - Jun Keng Khoo, A Bruce Montgomery, Kelly L Otto, Mark Surber, Jessica Faggian, Jason D Lickliter, Ian Glaspole. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Journal of aerosol medicine and pulmonary drug delivery.
2020 02; 33(1):15-20. doi:
10.1089/jamp.2018.1507. [PMID: 30698487] - Takumi Yoshikawa, Mitsuo Otsuka, Hirofumi Chiba, Kimiyuki Ikeda, Yuki Mori, Yasuaki Umeda, Hirotaka Nishikiori, Koji Kuronuma, Hiroki Takahashi. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
BMC pulmonary medicine.
2020 Jan; 20(1):27. doi:
10.1186/s12890-020-1060-y. [PMID: 32005219] - Haoshen Feng, Yabin Zhao, Zhenhua Li, Jian Kang. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Therapeutic advances in respiratory disease.
2020 Jan; 14(?):1753466620963015. doi:
10.1177/1753466620963015. [PMID: 33070705] - Laura Artigas, Mireia Coma, Pedro Matos-Filipe, Joaquim Aguirre-Plans, Judith Farrés, Raquel Valls, Narcis Fernandez-Fuentes, Juan de la Haba-Rodriguez, Alex Olvera, Jose Barbera, Rafael Morales, Baldo Oliva, Jose Manuel Mas. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
PloS one.
2020; 15(10):e0240149. doi:
10.1371/journal.pone.0240149. [PMID: 33006999] - Mostafa M Salah, Ahmed A Ashour, Tamer M Abdelghany, Abdel-Aziz H Abdel-Aziz, Salama A Salama. Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice.
Life sciences.
2019 Dec; 239(?):116982. doi:
10.1016/j.lfs.2019.116982. [PMID: 31639402] - Lisa M Kaminskas, Cornelia B Landersdorfer, Robert J Bischof, Nathania Leong, Jibriil Ibrahim, Andrew N Davies, Stephen Pham, Steven Beck, A Bruce Montgomery, Mark W Surber. Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis.
Pharmaceutical research.
2019 Dec; 37(1):3. doi:
10.1007/s11095-019-2732-2. [PMID: 31823096] - Xiaohe Li, Shuaishuai Liu, Yunqian Zhai, Xiangrong Cao, Shaoyan Gao, Mengying Huang, Yuanqiang Guo, Chunfeng Xie, Honggang Zhou. In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity.
Bioorganic & medicinal chemistry letters.
2019 11; 29(22):126695. doi:
10.1016/j.bmcl.2019.126695. [PMID: 31606345] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Marilyn K Glassberg, Steven D Nathan, Chin-Yu Lin, Elizabeth A Morgenthien, John L Stauffer, Willis Chou, Paul W Noble. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
Advances in therapy.
2019 10; 36(10):2910-2926. doi:
10.1007/s12325-019-01052-y. [PMID: 31401786] - Dalia H El-Kashef, Ahmed A Shaaban, Dina S El-Agamy. Protective role of pirfenidone against experimentally-induced pancreatitis.
Pharmacological reports : PR.
2019 Oct; 71(5):774-781. doi:
10.1016/j.pharep.2019.04.005. [PMID: 31376587] - Zhen-Zhen Qiu, Ji-Ming He, Hao-Xiang Zhang, Zuo-Hua Yu, Zhi-Wei Zhang, Hao Zhou. Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model.
Life sciences.
2019 Sep; 233(?):116666. doi:
10.1016/j.lfs.2019.116666. [PMID: 31325427] - Guanliang Chen, Yinhua Ni, Naoto Nagata, Liang Xu, Fen Zhuge, Mayumi Nagashimada, Shuichi Kaneko, Tsuguhito Ota. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
Laboratory investigation; a journal of technical methods and pathology.
2019 09; 99(9):1335-1348. doi:
10.1038/s41374-019-0255-4. [PMID: 31019294] - Young-Suk Kim, Hyunju Cha, Hyo-Jin Kim, Joong-Myung Cho, Hak-Ryul Kim. The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
Molecules (Basel, Switzerland).
2019 Jul; 24(15):. doi:
10.3390/molecules24152792. [PMID: 31370295] - Li-Jian Pang, Jian-Ping Liu, Xiao-Dong Lv. Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
Medicine.
2019 Jul; 98(30):e16325. doi:
10.1097/md.0000000000016325. [PMID: 31348231] - Chunhui Chen, Xueqing Yao, Yihua Xu, Qingyuan Zhang, Hao Wang, Liang Zhao, Ge Wen, Yawei Liu, Linlin Jing, Xuegang Sun. Dahuang Zhechong Pill suppresses colorectal cancer liver metastasis via ameliorating exosomal CCL2 primed pre-metastatic niche.
Journal of ethnopharmacology.
2019 Jun; 238(?):111878. doi:
10.1016/j.jep.2019.111878. [PMID: 30986521] - Yasuhiko Koga, Yoshimasa Hachisu, Hiroaki Tsurumaki, Masakiyo Yatomi, Kyoichi Kaira, Shoichiro Ohta, Junya Ono, Kenji Izuhara, Kunio Dobashi, Takeshi Hisada. Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
Medicina (Kaunas, Lithuania).
2019 May; 55(5):. doi:
10.3390/medicina55050161. [PMID: 31108995] - Dylan J Kahl, Kim M Hutchings, Erika Mathes Lisabeth, Andrew J Haak, Jeffrey R Leipprandt, Thomas Dexheimer, Dinesh Khanna, Pei-Suen Tsou, Phillip L Campbell, David A Fox, Bo Wen, Duxin Sun, Marc Bailie, Richard R Neubig, Scott D Larsen. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
Journal of medicinal chemistry.
2019 05; 62(9):4350-4369. doi:
10.1021/acs.jmedchem.8b01772. [PMID: 30951312] - Ixchel Lima-Posada, Francesco Fontana, Rosalba Pérez-Villalva, Nathan Berman-Parks, Norma A Bobadilla. Pirfenidone prevents acute kidney injury in the rat.
BMC nephrology.
2019 05; 20(1):158. doi:
10.1186/s12882-019-1364-4. [PMID: 31068174] - Xuhua Han, Fang Li, Zhou Wen, Yuehui Ma, Lei Wang, Zeneng Cheng. Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative.
Clinical and experimental pharmacology & physiology.
2019 05; 46(5):465-474. doi:
10.1111/1440-1681.13078. [PMID: 30815895] - Jianshuang Wang, Michael Van Parys, Lin Pan, Yuan Chen, Dorothy Cheung, Janine McKnight, Dennis Milanowski, Xiao Ding, Brian Dean. Determination of a novel antifibrotic small molecule GDC-3280 in human plasma and urine by liquid chromatography tandem mass spectrometry to support its first-in-human clinical trial.
Biomedical chromatography : BMC.
2019 Apr; 33(4):e4482. doi:
10.1002/bmc.4482. [PMID: 30618197] - Luca Richeldi, Sophie Fletcher, Huzaifa Adamali, Nazia Chaudhuri, Sabrina Wiebe, Sven Wind, Kathrin Hohl, Andrew Baker, Rozsa Schlenker-Herceg, Susanne Stowasser, Toby M Maher. No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
The European respiratory journal.
2019 01; 53(1):. doi:
10.1183/13993003.01060-2018. [PMID: 30442716] - Hiroshi Ishii, Yoshiaki Kinoshita, Hisako Kushima, Nobuhiko Nagata, Kentaro Watanabe. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.
Chronic respiratory disease.
2019 Jan; 16(?):1479973119867945. doi:
10.1177/1479973119867945. [PMID: 31387379] - Jeffrey D Pope, Olaf H Drummer, Hans G Schneider. Pirfenidone causes false-positive urine benzodiazepine results: Implications for patients with pulmonary fibrosis.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
2018 12; 37(12):1475-1477. doi:
10.1016/j.healun.2018.09.014. [PMID: 30447853] - Grazyna Kwapiszewska, Anna Gungl, Jochen Wilhelm, Leigh M Marsh, Helene Thekkekara Puthenparampil, Katharina Sinn, Miroslava Didiasova, Walter Klepetko, Djuro Kosanovic, Ralph T Schermuly, Lukasz Wujak, Benjamin Weiss, Liliana Schaefer, Marc Schneider, Michael Kreuter, Andrea Olschewski, Werner Seeger, Horst Olschewski, Malgorzata Wygrecka. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.
The European respiratory journal.
2018 11; 52(5):. doi:
10.1183/13993003.00564-2018. [PMID: 30166321] - Nicola Ronan, Deirdre M Bennett, Kashif A Khan, Yvonne McCarthy, Darren Dahly, Louise Bourke, Adeline Chelliah, Alberto Cavazza, Kevin O'Regan, Fiachra Moloney, Barry J Plant, Michael T Henry. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
Lung.
2018 10; 196(5):543-552. doi:
10.1007/s00408-018-0140-8. [PMID: 30066212] - Yoshitaka Isaka. Targeting TGF-β Signaling in Kidney Fibrosis.
International journal of molecular sciences.
2018 Aug; 19(9):. doi:
10.3390/ijms19092532. [PMID: 30150520] - Margaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, X Rebecca Sheng, Gaik W Tew, Chunyan Gu, Guiquan Jia, Kun Peng, Jill M Ray, Brett Ley, Paul J Wolters, Harold R Collard, Joseph R Arron. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
The Lancet. Respiratory medicine.
2018 08; 6(8):615-626. doi:
10.1016/s2213-2600(18)30185-1. [PMID: 30072107] - Lin Pan, Thomas Gelzleichter, Yuan Chen, Cindy Burg, Susan L Limb, Linda Nguyen. Effect of pirfenidone on gastric emptying in a rat model.
Pulmonary pharmacology & therapeutics.
2018 08; 51(?):41-47. doi:
10.1016/j.pupt.2018.06.001. [PMID: 29944949] - Naga Gayatri Sambhani, Valsala Madhavan Nair Biju. A Micelle-Enhanced Spectrofluorimetric Determination of Pirfenidone: Application to Content Uniformity Testing and Human Urine.
Journal of fluorescence.
2018 Jul; 28(4):951-957. doi:
10.1007/s10895-018-2258-8. [PMID: 29974315] - Yi Li, Haitao Li, Shuai Liu, Pinhua Pan, Xiaoli Su, Hongyi Tan, Dongdong Wu, Lemeng Zhang, Chao Song, Minhui Dai, Qian Li, Zhi Mao, Yuan Long, Yongbin Hu, Chengping Hu. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Molecular immunology.
2018 07; 99(?):134-144. doi:
10.1016/j.molimm.2018.05.003. [PMID: 29783158] - Yangkui Gu, Govindarajan Srimathveeravalli, Liqun Cai, Eisuke Ueshima, Majid Maybody, Hooman Yarmohammadi, Yuan-Shan Zhu, Jeremy C Durack, Stephen B Solomon, Jonathan A Coleman, Joseph P Erinjeri. Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model.
Cryobiology.
2018 06; 82(?):106-111. doi:
10.1016/j.cryobiol.2018.03.012. [PMID: 29621494] - Michel R Corboz, Jimin Zhang, Daniel LaSala, Keith DiPetrillo, Zhili Li, Vladimir Malinin, Jeremy Brower, Philip J Kuehl, Ted E Barrett, Walter R Perkins, Richard W Chapman. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
Pulmonary pharmacology & therapeutics.
2018 04; 49(?):95-103. doi:
10.1016/j.pupt.2018.01.012. [PMID: 29408757] - Fateme Pourgholamhossein, Rokhsana Rasooli, Mostafa Pournamdari, Leyla Pourgholi, Mitra Samareh-Fekri, Mahmoud Ghazi-Khansari, Maryam Iranpour, Hamid-Reza Poursalehi, Mahmoud-Reza Heidari, Ali Mandegary. Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2018 Feb; 112(?):39-46. doi:
10.1016/j.fct.2017.12.034. [PMID: 29273418] - Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Wim A Wuyts. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
American journal of respiratory and critical care medicine.
2018 02; 197(3):356-363. doi:
10.1164/rccm.201706-1301oc. [PMID: 28889759] - Jun Chen, Zhangzhe Peng, Miaomiao Lu, Xuan Xiong, Zhuo Chen, Qianbin Li, Zeneng Cheng, Dejian Jiang, Lijian Tao, Gaoyun Hu. Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Bioorganic & medicinal chemistry letters.
2018 01; 28(2):222-229. doi:
10.1016/j.bmcl.2017.07.001. [PMID: 29248299] - Deva D Chan, Jun Li, Wei Luo, Dan N Predescu, Brian J Cole, Anna Plaas. Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
2018 01; 36(1):365-376. doi:
10.1002/jor.23635. [PMID: 28646530] - Jianshe Ma, Fa Sun, Bingbao Chen, Xiaoting Tu, Xiufa Peng, Congcong Wen, Lufeng Hu, Xianqin Wang. Tissue metabolic changes for effects of pirfenidone in rats of acute paraquat poisoning by GC-MS.
Toxicology and industrial health.
2017 Dec; 33(12):887-900. doi:
10.1177/0748233717731959. [PMID: 28978283] - Merel L Kimman, Adrienne H Rotteveel, Marlies Wijsenbeek, Rémy Mostard, Nelleke C Tak, Xana van Jaarsveld, Marjolein Storm, Kioa L Wijnsma, Marielle Gelens, Nicole C A J van de Kar, Jack Wetzels, Carmen D Dirksen. Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).
The patient.
2017 Oct; 10(5):629-642. doi:
10.1007/s40271-017-0234-z. [PMID: 28357591] - Kimiyuki Ikeda, Masanori Shiratori, Hirofumi Chiba, Hirotaka Nishikiori, Keiki Yokoo, Atsushi Saito, Yoshihiro Hasegawa, Koji Kuronuma, Mitsuo Otsuka, Gen Yamada, Hiroki Takahashi. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Respiratory medicine.
2017 10; 131(?):184-191. doi:
10.1016/j.rmed.2017.08.021. [PMID: 28947028] - Lin Pan, Paula Belloni, Han Ting Ding, Jianshuang Wang, Christopher M Rubino, Wendy S Putnam. A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers.
Advances in therapy.
2017 09; 34(9):2071-2082. doi:
10.1007/s12325-017-0594-8. [PMID: 28808905] - Zhenzhen Li, Xianghua Liu, Baoying Wang, Yali Nie, Jianguo Wen, Qingwei Wang, Chaohui Gu. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
Nephrology (Carlton, Vic.).
2017 Aug; 22(8):589-597. doi:
10.1111/nep.12831. [PMID: 27245114] - Nicolas Desroy, Christopher Housseman, Xavier Bock, Agnès Joncour, Natacha Bienvenu, Laëtitia Cherel, Virginie Labeguere, Emilie Rondet, Christophe Peixoto, Jean-Marie Grassot, Olivier Picolet, Denis Annoot, Nicolas Triballeau, Alain Monjardet, Emanuelle Wakselman, Veronique Roncoroni, Sandrine Le Tallec, Roland Blanque, Celine Cottereaux, Nele Vandervoort, Thierry Christophe, Patrick Mollat, Marieke Lamers, Marielle Auberval, Boska Hrvacic, Jovica Ralic, Line Oste, Ellen van der Aar, Reginald Brys, Bertrand Heckmann. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Journal of medicinal chemistry.
2017 05; 60(9):3580-3590. doi:
10.1021/acs.jmedchem.7b00032. [PMID: 28414242] - Yuan Liu, Fuai Lu, Lirong Kang, Zhihua Wang, Yongfu Wang. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.
BMC pulmonary medicine.
2017 04; 17(1):63. doi:
10.1186/s12890-017-0405-7. [PMID: 28420366] - Barbara M Klinkhammer, Roel Goldschmeding, Jürgen Floege, Peter Boor. Treatment of Renal Fibrosis-Turning Challenges into Opportunities.
Advances in chronic kidney disease.
2017 03; 24(2):117-129. doi:
10.1053/j.ackd.2016.11.002. [PMID: 28284377] - Xingren Liu, Yifeng Bai, Liang Liang, Jing Feng, Fei Deng. [Salidroside improves pulmonary fibrosis by down-regulation of cathepsin B and NF-κBp65 in rats].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.
2017 Feb; 42(2):128-133. doi:
10.11817/j.issn.1672-7347.2017.02.002. [PMID: 28255112] - Kentaro Wakamatsu, Nobuhiko Nagata, Hiroyuki Kumazoe, Keishi Oda, Hiroshi Ishimoto, Michihiro Yoshimi, Shohei Takata, Minako Hamada, Yoshifusa Koreeda, Kouji Takakura, Miwa Ishizu, Makiko Hara, Shinji Ise, Miiru Izumi, Takashi Akasaki, Sanae Maki, Masaharu Kawabata, Hiroshi Mukae, Masayuki Kawasaki. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis.
Respiratory investigation.
2017 Jan; 55(1):16-23. doi:
10.1016/j.resinv.2016.09.003. [PMID: 28012488] - Ganesh Raghu, Kevin K Brown, Harold R Collard, Vincent Cottin, Kevin F Gibson, Robert J Kaner, David J Lederer, Fernando J Martinez, Paul W Noble, Jin Woo Song, Athol U Wells, Timothy P M Whelan, Wim Wuyts, Emmanuel Moreau, Scott D Patterson, Victoria Smith, Selina Bayly, Jason W Chien, Qi Gong, Jenny J Zhang, Thomas G O'Riordan. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
The Lancet. Respiratory medicine.
2017 01; 5(1):22-32. doi:
10.1016/s2213-2600(16)30421-0. [PMID: 27939076] - Sonali G Thorat, Rupesh V Chikhale. Determination and Pharmacokinetic Study of Pirfenidone in Rat Serum by High-Performance Thin-Layer Chromatography.
Journal of chromatographic science.
2016 Aug; 54(7):1115-9. doi:
10.1093/chromsci/bmw067. [PMID: 27406123] - Li Wang, Feng-Chun Zhang, Xuan Zhang. Therapeutic advances for primary biliary cholangitis: the old and the new.
European journal of gastroenterology & hepatology.
2016 Jun; 28(6):615-21. doi:
10.1097/meg.0000000000000591. [PMID: 26862931] - J Guiot, B Bondue, M Henket, J L Corhay, R Louis. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.
BMC pulmonary medicine.
2016 May; 16(1):86. doi:
10.1186/s12890-016-0249-6. [PMID: 27215343] - Min Xiao, Xiao-Hu Qu, Jv-Ping Lv, Yang Shi, Chang-Xi Li, Ke-Jian Xie. [Effects of pirfenidone on hepatic fibrosis in mice induced by carbon tetrachloride].
Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology.
2016 Apr; 32(4):378-382. doi:
10.13459/j.cnki.cjap.2016.04.023. [PMID: 29931966] - Na Sun, Isis E Fernandez, Mian Wei, Yin Wu, Michaela Aichler, Oliver Eickelberg, Axel Walch. Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.
Histochemistry and cell biology.
2016 Feb; 145(2):201-11. doi:
10.1007/s00418-015-1382-7. [PMID: 26645566] - Simona Zanotti, Cinzia Bragato, Andrea Zucchella, Lorenzo Maggi, Renato Mantegazza, Lucia Morandi, Marina Mora. Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients.
Life sciences.
2016 Jan; 145(?):127-36. doi:
10.1016/j.lfs.2015.12.015. [PMID: 26679108] - Manuela Funke-Chambour, Thomas Geiser. [Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
Therapeutische Umschau. Revue therapeutique.
2016; 73(1):25-9. doi:
10.1024/0040-5930/a000751. [PMID: 26884217] - Jinqing Hu, Dewei Shang, Xinwen Xu, Xiuling He, Xiaojia Ni, Ming Zhang, Zhanzhang Wang, Chang Qiu, Shuhua Deng, Haoyang Lu, Xiuqing Zhu, Wencan Huang, Yuguan Wen. Effect of grapefruit juice and food on the pharmacokinetics of pirfenidone in healthy Chinese volunteers: a diet-drug interaction study.
Xenobiotica; the fate of foreign compounds in biological systems.
2016; 46(6):516-21. doi:
10.3109/00498254.2015.1089365. [PMID: 26407124]